

# Laura Bonanno

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/104633/publications.pdf>

Version: 2024-02-01

68  
papers

1,884  
citations

304743

22  
h-index

289244

40  
g-index

72  
all docs

72  
docs citations

72  
times ranked

3240  
citing authors

#	ARTICLE	IF	CITATIONS
1	Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. <i>Blood</i> , 2011, 117, 7053-7062.	1.4	199
2	Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. <i>Oncologist</i> , 2019, 24, 1128-1136.	3.7	156
3	Crizotinib in <i>MET</i> -Deregulated or <i>ROS1</i> -Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. <i>Clinical Cancer Research</i> , 2019, 25, 7312-7319.	7.0	139
4	Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4647-4659.	7.0	130
5	The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes. <i>European Journal of Cancer</i> , 2018, 101, 191-200.	2.8	86
6	Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. <i>Cancer Treatment Reviews</i> , 2020, 87, 102031.	7.7	82
7	Notch3 signalling promotes tumour growth in colorectal cancer. <i>Journal of Pathology</i> , 2011, 224, 448-460.	4.5	77
8	Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges. , 2019, 7, 205.		72
9	18F-FDG PET/CT in non-small-cell lung cancer patients. <i>Nuclear Medicine Communications</i> , 2019, 40, 802-807.	1.1	63
10	<i>ROS1</i> -rearranged Non-Small Cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). <i>Clinical Lung Cancer</i> , 2020, 21, 15-20.	2.6	58
11	<i>LKB1</i> Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. <i>Clinical Cancer Research</i> , 2017, 23, 3316-3324.	7.0	43
12	Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 2585-2592.	1.6	42
13	Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 30-39.	4.4	40
14	Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. <i>Clinical Lung Cancer</i> , 2019, 20, e186-e194.	2.6	40
15	<i>LKB1</i> and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1874.	4.1	39
16	Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?. <i>British Journal of Cancer</i> , 2022, 127, 383-393.	6.4	36
17	Early assessment of <i>KRAS</i> mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2020, 123, 81-91.	6.4	35
18	<i>STAT3</i> as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876374.	3.2	30

#	ARTICLE	IF	CITATIONS
19	Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. <i>Translational Lung Cancer Research</i> , 2021, 10, 202-220.	2.8	29
20	Neutrophilâ€“lymphocyte ratio is prognostic in early stage resected small-cell lung cancer. <i>PeerJ</i> , 2019, 7, e7232.	2.0	27
21	Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature. <i>Cancer Biology and Therapy</i> , 2015, 16, 1128-1135.	3.4	26
22	Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer. <i>Current Drug Targets</i> , 2011, 12, 922-933.	2.1	25
23	First-Line Osimertinib in Patients with <i>EGFR</i> -Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. <i>Oncologist</i> , 2022, 27, 87-e115.	3.7	25
24	Role of Genotyping in Non-Small Cell Lung Cancer Treatment. <i>Drugs</i> , 2011, 71, 2231-2246.	10.9	23
25	The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. <i>Oncotarget</i> , 2013, 4, 1572-1581.	1.8	23
26	Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer. <i>BMC Cancer</i> , 2016, 16, 312.	2.6	21
27	Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1021-1030.	2.4	21
28	Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience. <i>Oncologist</i> , 2020, 25, e1996-e2005.	3.7	21
29	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative <i>EGFR</i> Mutant Nonâ€“small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. <i>Clinical Lung Cancer</i> , 2020, 21, 1-14.e3.	2.6	19
30	The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. <i>Annals of Oncology</i> , 2013, 24, 1130-1132.	1.2	17
31	Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 87-103.	4.4	16
32	Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 128, 19-29.	4.4	14
33	Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. <i>Oncotarget</i> , 2017, 8, 32626-32638.	1.8	14
34	Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptorâ€“Mutated Nonâ€“Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2286-2296.	7.0	14
35	Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: A mono-institutional experience. <i>Lung Cancer</i> , 2011, 73, 351-355.	2.0	12
36	Detection of Loss of Heterozygosity in cfDNA of Advanced <i>EGFR</i> - or <i>KRAS</i> -Mutated Non-Small-Cell Lung Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 66.	4.1	12

#	ARTICLE	IF	CITATIONS
37	Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: Translating scientific evidence into clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103378.	4.4	12
38	Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2013, 2, 160-71.	2.8	11
39	Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature. <i>American Journal of Case Reports</i> , 2015, 16, 782-789.	0.8	10
40	A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients. <i>Lung Cancer</i> , 2017, 108, 15-21.	2.0	10
41	Does Induction Therapy Increase Anastomotic Complications in Bronchial Sleeve Resections?. <i>World Journal of Surgery</i> , 2019, 43, 1385-1392.	1.6	10
42	Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 607840.	2.8	10
43	Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman. <i>Lung Cancer</i> , 2016, 96, 52-55.	2.0	8
44	Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy. <i>Journal of Thoracic Oncology</i> , 2019, 14, e5-e7.	1.1	7
45	Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 564915.	2.8	7
46	SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1810-1821.	2.8	7
47	Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1601.	4.1	7
48	Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. <i>Future Oncology</i> , 2021, 17, 2513-2527.	2.4	7
49	Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization. <i>Oncotarget</i> , 2016, 7, 25050-25063.	1.8	6
50	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	3.7	6
51	Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials. <i>Lung Cancer</i> , 2019, 133, 62-68.	2.0	5
52	Efficacy of the addition of cisplatin to single-agent first-line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): A joint analysis of the multicenter, randomized phase III MILES-3 and MILES-4 studies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9002-9002.	1.6	5
53	From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study). <i>Oncologist</i> , 2019, 24, e318-e326.	3.7	5
54	Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. <i>Lung Cancer</i> , 2019, 134, 121-126.	2.0	4

#	ARTICLE	IF	CITATIONS
55	ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs. CAV or topotecan (T) in small-cell lung cancer after platinum therapy.. Journal of Clinical Oncology, 2018, 36, TPS8587-TPS8587.	1.6	4
56	Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment. OncoTargets and Therapy, 2016, 9, 3671.	2.0	3
57	Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Future Oncology, 2018, 14, 353-361.	2.4	3
58	OUP accepted manuscript. Oncologist, 2022, , .	3.7	3
59	Unusual echocardiographic appearance of a cardiac metastasis from lung carcinoma. Journal of Clinical Ultrasound, 2016, 44, 392-394.	0.8	2
60	Assessment of chromosomal rearrangements helps to differentiate multiple lung primary cancers from metastases. Translational Lung Cancer Research, 2019, 8, S435-S438.	2.8	2
61	77P Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): An exploratory analysis in advanced non-small cell lung cancer (A-NSCLC). Journal of Thoracic Oncology, 2016, 11, S88.	1.1	1
62	211P: Inflammatory cells characterization and localization in malignant pleural mesothelioma (MPM) tissue samples: Correlation with histologic subtype and prognosis. Journal of Thoracic Oncology, 2016, 11, S148.	1.1	1
63	Editorial on "The AvaALL Randomized Clinical Trial". Journal of Thoracic Disease, 2019, 11, S1237-S1240.	1.4	1
64	166P: Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations: A single institution series. Journal of Thoracic Oncology, 2016, 11, S130.	1.1	0
65	28P Different genetic profiling in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD): An exploratory analysis by next generation sequencing (NGS). Journal of Thoracic Oncology, 2016, 11, S67.	1.1	0
66	IPA-3 (PAK1 inhibitor) or OTSSP167 (MELK inhibitor) plus auranofin (PKC $\alpha$ 1 inhibitor), a therapeutic option for EGFR mutant, KRAS mutant and squamous cell non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, e24001-e24001.	1.6	0
67	Monitoring advanced non-small cell lung cancer (NSCLC) through plasma genotyping during systemic treatment: KRAS-mutated (m) cohort results.. Journal of Clinical Oncology, 2018, 36, e24074-e24074.	1.6	0
68	Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC.. Journal of Clinical Oncology, 2019, 37, e20612-e20612.	1.6	0